CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
Immunotherapy is a promising therapeutic area in cancer and chronic viral infections. An important component of immunotherapy in these contexts is the activation of innate immunity. Here we investigate the potential for CD169 (Siglec 1) expression on monocytes to serve as a robust biomarker for acti...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2022-07-01
|
| Col·lecció: | Frontiers in Cellular and Infection Microbiology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fcimb.2022.919097/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|